Abstract
INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.
METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.
RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.
CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.
| Original language | English |
|---|---|
| Pages (from-to) | 154-9 |
| Number of pages | 6 |
| Journal | Leukemia research |
| Volume | 34 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2010 |
| Externally published | Yes |
Keywords
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- Child
- Child, Preschool
- Cytochrome P-450 CYP3A/genetics
- Drug Resistance, Neoplasm/genetics
- Female
- Genotype
- Humans
- Male
- Pharmacogenetics
- Polymorphism, Genetic
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
- Psychomotor Performance/drug effects
- Vincristine/pharmacokinetics
- tau Proteins/genetics